Premium
Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study
Author(s) -
Ishiwata A.,
Sakayori O.,
Minoshima S.,
Mizumura S.,
Kitamura S.,
Katayama Y.
Publication year - 2006
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2006.00661.x
Subject(s) - cognitive impairment , perfusion , medicine , posterior cingulate , alzheimer's disease , spect imaging , positron emission tomography , single photon emission computed tomography , psychology , nuclear medicine , neuroscience , cardiology , cognition , audiology , disease
Objectives – Baseline brain single‐photon emission computed tomography (SPECT) can predict mild cognitive impairment (MCI) patients at risk for progressive MCI (PMCI). Methods – Twenty‐eight subjects [12 MCI, 6 with probable Alzheimer's Disease (AD), and 10 normal subjects] underwent baseline brain SPECT and were clinically followed for a mean period of 36 months. Results – Of 12 MCI patients, 6 progressed to PMCI and 6 remained stable. Baseline SPECT identified asymmetric perfusion reduction in the parahippocampus (−5%), lateral parietal (−8%), and posterior cingulate (−11%) cortices – reductions consistent with that of mild AD – in five of the six PMCI patients. Significant perfusion reduction was observed particularly in the frontal cortices of probable AD when compared with PMCI ( P < 0.05). Conclusion – Baseline SPECT can identify brain perfusion abnormalities among patients with MCI for progression to PMCI. This imaging modality may aid in MCI treatment stratification.